Log in to search using one of your social media accounts:

 

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
FRANKFURT (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

More Than Okay to Reduce Sorafenib Dose for Liver Cancer More Than Okay to Reduce Sorafenib Dose for Liver Cancer
Initially reducing the dosage of the oral therapy did not compromise overall survival in hepatocellular carcinoma and had important benefits.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tailored Treatment for Head-and-Neck Cancer Mystery
Treatment TermsHead and Neck Cancer Overview Rob Vaughn found a lump on his neck that turned out to be cancer that had spread from somewhere else in his body. The trouble was, doctors couldn ’t find the original site of the cancer. That made his treatment decisions difficult -- until two Duke specialists offered him options, including the option for watchful waiting instead of extensive treatment. Hero Image20170914_robvaughn_neckcancer_083_herocrop.jpg Preview Image Content Blocks Header A Search for the Source of Cancer ContentVaughn, a Charlotte, NC, father of two, was 47 and in good health when he felt th...
Source: dukehealth.org: Duke Health News - September 15, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Adrenocortical Carcinoma
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

Is There a Standard for Surgical Therapy of HCC? Is There a Standard for Surgical Therapy of HCC?
This study compared different guidelines regarding indication for resection and transplantation in patients with hepatocellular carcinoma, with and without underlying cirrhosis. Is there a consensus?BMJ Open Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC
Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

Regeneron and Sanofi receive FDA ’s breakthrough therapy status for CSCC treatment with cemiplimab
US-based Regeneron Pharmaceuticals and French company Sanofi have received breakthrough therapy designation status for cemiplimab (REGN2810) from the US Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 10, 2017 Category: Pharmaceuticals Source Type: news

Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma[1], [2]. Cemiplimab is an investigational human, monoclonal antibody targeting PD-1. (Source: World Pharma News)
Source: World Pharma News - September 8, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Sept. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation s... Biopharmaceuticals, Oncology Regeneron Pharmaceuticals, Sanofi, cemiplimab, cutaneous squamous cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2017 Category: Pharmaceuticals Source Type: news

Hepatocellular carcinoma: Resection vs. transplantation
(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2017 Category: Cancer & Oncology Source Type: news

Unrelenting NHS pressure affecting cancer care, say GPs and nurses
Half of GPs and primary care nurses not confident NHS workforce can provide adequate care Related items fromOnMedica Nasopharyngeal carcinoma and sinus cancer UK spends 20% less on cancer treatment than rest of EU Fifteen local NHS transformation projects to get cash boost The genetics of breast cancer Meeting cancer promises and more – a new model for NHS diagnostics? (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 8, 2017 Category: UK Health Source Type: news

BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Rare Neuroendocrine Breast Cancer Not So Unusual Rare Neuroendocrine Breast Cancer Not So Unusual
Neuroendocrine breast cancer can be indistinguishable from high-grade ductal carcinoma, although treatment is different, and can be missed unless stained specifically for neuroendocrine markers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 7, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news

Local DCIS Recurrence After Skipping Adjuvant Radiation Local DCIS Recurrence After Skipping Adjuvant Radiation
Omitting radiation after lumpectomy for pure ductal carcinoma in situ (DCIS) does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Crosstalk Identified Between Adipose Tissue, Carcinomas
Organ - dependent crosstalk identified via VEGF, IL6, TNF α , and other mechanisms (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 1, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Nursing, Oncology, ENT, Pathology, Pulmonology, Radiology, Surgery, Urology, Journal, Source Type: news

European Commission licences EUSA ’s advanced RCC treatment fotivda
Jazz Pharmaceuticals subsidiary EUSA Pharma ’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Translocation Renal Cell Carcinoma: An Update
Microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC) comprises Xp11 tRCC and t(6;11) RCC.08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

AVEO Pharma stock rises 6% after cancer drug gets approved
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

Telomere Length Prognostic in Hepatocellular Carcinoma
Shortened telomeres in tumor cells, CA - associated fibroblasts tied to reduced survival, upped recurrence (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 24, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Sirtex swings to a loss after ‘ challenging ’ year
Shares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before. Sirtex has faced a barrage of obstacles this year, including a number of clinical trials that failed to meet primary endpoints. The company’s full-year results were hit by a slowdown in sales growth of its SIR-Spheres Y-90 radioactive microspheres and by the costs linked to its restructuring efforts. In June, Sirtex said it planned to cut 15% of its workforce, estimating that it would sav...
Source: Mass Device - August 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Source Type: news

Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment
(Bentham Science Publishers) Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer that is highly prevalent among men in the populations of Southern China and Southeast Asia. This review will discuss the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 23, 2017 Category: Cancer & Oncology Source Type: news

Longer Telomeres Linked to Renal-cell Carcinoma Risk Longer Telomeres Linked to Renal-cell Carcinoma Risk
Genetic variants that predispose individuals to longer telomere length appear to be associated with an increased risk of renal-cell carcinoma (RCC), according to results from a genome-wide association studies (GWAS) database analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Newly developed nomograms provide accurate predictions for patients with oropharyngeal cancer
(NRG Oncology) NRG Oncology researchers recently developed and validated a nomogram that can predict 2-year and 5-year overall survival (OS) and progression-free survival (PFS) for patients with local-regionally advanced oropharyngeal squamous cell carcinoma (OPSCC) treated primarily with radiation-based therapy. This nomogram was developed with data from clinical trials NRG Oncology/RTOG 0129 and 0522. Results were published online in the Journal of Clinical Oncology on Aug. 4, 2017. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 21, 2017 Category: Cancer & Oncology Source Type: news

Exelixis Submits sNDA for Kidney Cancer Drug
The sNDA submission was based on positive results from phase II trial, CABOSUN, in patients with previously untreated advanced RCC with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).08/20/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news

Nodal Stage Migration in Anal Cancer May Misclassify True Disease Stage
The rate of lymph node positivity in patients with squamous cell carcinoma of the anus may be overestimated, potentially leading to the overtreatment of patients with chemoradiotherapy. (Source: CancerNetwork)
Source: CancerNetwork - August 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Gastrointestinal Cancer News Source Type: news

Anal Cancer More Deadly in Black Men
Significant racial and gender-based disparities exist in outcomes among patients with squamous cell carcinoma of the anus, with black men having the lowest survival rates, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 18, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Gastrointestinal Cancer News Source Type: news

Iovance commences LN-145 dosing in Phase II trial for cervical cancer
US-based biotechnology firm Iovance Biotherapeutics has commenced patient dosing in its Phase II C-145-04 clinical trial of LN-145 to treat recurrent, metastatic or persistent cervical carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 16, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 16, 2017 Category: Urology & Nephrology Source Type: news

BMS Phase III ’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: Camille Berriochoa, MD Carisa Bohnak, BS Chirag Shah, MD Nicole Chahine, BS Tags: Breast Cancer Oncology Journal Source Type: news

COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: William C. Wood, MD Tags: Breast Cancer Oncology Journal Source Type: news

Bristol-Myers Squibb announces topline results from CheckMate -214
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma. (Source: World Pharma News)
Source: World Pharma News - August 15, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

How Do Direct-Acting Antivirals for HCV Affect HCC Risk? How Do Direct-Acting Antivirals for HCV Affect HCC Risk?
The latest data on the controversial hepatitis C-hepatocellular carcinoma treatment link are examined.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Liquid biopsies find distinct genomic profiles in most patients with carcinoma of unknown primary
(American Association for Cancer Research) Next-generation sequencing of circulating tumor DNA identified distinct genomic profiles with potentially targetable alterations in 99.7 percent of patients with carcinoma of unknown primary who have detectable alterations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 15, 2017 Category: Cancer & Oncology Source Type: news

Positive Surgical Margins in RCC More Common Among African Americans
African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients. (Source: CancerNetwork)
Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Immunicum starts enrolment in US for Phase II oncology trial
Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news

Early Detection of Nasopharyngeal Cancer With EBV DNA Early Detection of Nasopharyngeal Cancer With EBV DNA
Screening for Epstein-Barr virus DNA in plasma samples identified nasopharyngeal carcinoma significantly earlier compared with historical controls.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Analysis of EBV DNA in Plasma Samples IDs Nasopharyngeal CA
Screening detects nasopharyngeal carcinoma significantly earlier; linked to better outcomes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 10, 2017 Category: Cancer & Oncology Tags: Infections, Oncology, ENT, Journal, Source Type: news

NICE recommends Merck ’s erbitux to treat R/M SCCHN in oral cavity
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck ’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma
Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus) ‎ for the treatment of patients with renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Bayer ’s stivarga receives EU marketing approval for HCC treatment
The European Commission (EC) has granted marketing authorisation for Bayer ’s stivarga (regorafenib) used for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with nexavar (sorafenib). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Alcohol linked to an increased risk of skin cancer
Conclusion These findings should be interpreted with care before concluding that an alcoholic drink per day increases your risk of skin cancer. There are several important cautions: These are only observational studies. It wouldn't be possible to randomise people to different alcohol intake and follow them to look at cancer development. And with observational studies, many other health, sociodemographic and lifestyle factors may be influencing the link between alcohol intake and cancer development. The studies differed considerably in terms of the influencing factors they took account of, with some adjusting for various ...
Source: NHS News Feed - August 7, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Bayer Receives EU Approval for Stivarga ® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States fo r patients with HCC (Source: Bayer Company News)
Source: Bayer Company News - August 7, 2017 Category: Pharmaceuticals Source Type: news

Fibromatosis-like Spindle Cell Carcinoma of the Breast Fibromatosis-like Spindle Cell Carcinoma of the Breast
This case describes the clinical and imaging findings of a rare triple negative, fibromatosis-like metaplastic spindle cell breast carcinoma.Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 7, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Bladder Preservation Yields Poorer Survival in Urothelial Carcinoma
In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study. (Source: CancerNetwork)
Source: CancerNetwork - August 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Knoxville woman records her fight with deadly skin cancer
Marisha Dotson, 28, from Knoxville in Tennessee, has lost her nose, parts of her jaw and eight teeth during her battle with squamous cell carcinoma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2017 Category: Consumer Health News Source Type: news

Orphan, 28, documents her battle with deadly skin cancer
Marisha Dotson, 28, from Knoxville in Tennessee, has lost her nose, parts of her jaw and eight teeth during her battle with squamous cell carcinoma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2017 Category: Consumer Health News Source Type: news

Breakthrough in tackling aggressive cancers
Finding could lead to new treatments Related items fromOnMedica Nasopharyngeal carcinoma and sinus cancer Underused cancer test could improve treatment of colon cancer Blood test may pick up bladder cancer ’s return before symptoms appear Tall men at higher risk of aggressive prostate cancer UK spends 20% less on cancer treatment than rest of EU (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 3, 2017 Category: UK Health Source Type: news